Legal Insights

Perspectives on Cannabis, Hemp, Beverage and Psychedelic Law

Senator McConnell Prods FDA Regarding Hemp-Derived CBD Regulation
New and Pending Legislation
Rogoway Law Group

Senator McConnell Prods FDA Regarding Regulation of Hemp-Derived CBD and Derivative Products

On September 17, Senate Majority Leader Mitch McConnell submitted language into a congressional spending report which will force the FDA to reveal their policy on hemp-derived CBD enforcement sooner rather than later.  If approved by the Senate, the amended spending report could provide clarity for industry stakeholders and banks on the sidelines who eagerly await participation in the hemp-derived CBD

Read More »
FDA's Hemp Regulations Post AIA
New and Pending Legislation
Rogoway Law Group

FDA Regulation of Hemp Post Agricultural Improvement Act of 2018

On December 20, 2018, the Agricultural Improvement Act (“AIA”) of 2018 was signed into law. Among the changes made within the AIA was the long-awaited legalization of industrial hemp. The AIA removes hemp (defined as cannabis and derivatives of cannabis with less than 0.3% THC on a dry weight basis) from the Controlled Substances Act (“CSA”). This removal of hemp

Read More »
Federal
Rogoway Law Group

FDA Approves Epidiolex: First Therapeutic Drug Made From Plant-Derived CBD

Co-Author: Josh Zetlin This week the U.S. Food and Drug Administration (FDA) approved Epidiolex as a treatment for seizures associated with two rare and severe forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. Epidiolex, developed by GW Pharmaceuticals plc (Nasdaq: GWPH), a UK-based pharmaceutical company with U.S. operations, is the first FDA-approved drug made from a purified substance derived from

Read More »